OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL-Rearranged Leukemia
Carly Campbell, Jessica N. Haladyna, David A. Drubin, et al.
Molecular Cancer Therapeutics (2017) Vol. 16, Iss. 8, pp. 1669-1679
Open Access | Times Cited: 53
Carly Campbell, Jessica N. Haladyna, David A. Drubin, et al.
Molecular Cancer Therapeutics (2017) Vol. 16, Iss. 8, pp. 1669-1679
Open Access | Times Cited: 53
Showing 1-25 of 53 citing articles:
An Epigenetic Role of Mitochondria in Cancer
Yue Liu, Chao Chen, Xinye Wang, et al.
Cells (2022) Vol. 11, Iss. 16, pp. 2518-2518
Open Access | Times Cited: 87
Yue Liu, Chao Chen, Xinye Wang, et al.
Cells (2022) Vol. 11, Iss. 16, pp. 2518-2518
Open Access | Times Cited: 87
The Chemical Biology of Reversible Lysine Post-translational Modifications
Zhipeng A. Wang, Philip A. Cole
Cell chemical biology (2020) Vol. 27, Iss. 8, pp. 953-969
Open Access | Times Cited: 131
Zhipeng A. Wang, Philip A. Cole
Cell chemical biology (2020) Vol. 27, Iss. 8, pp. 953-969
Open Access | Times Cited: 131
Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis
Masayuki Yamashita, Paul V. Dellorusso, Oakley C. Olson, et al.
Nature reviews. Cancer (2020) Vol. 20, Iss. 7, pp. 365-382
Open Access | Times Cited: 128
Masayuki Yamashita, Paul V. Dellorusso, Oakley C. Olson, et al.
Nature reviews. Cancer (2020) Vol. 20, Iss. 7, pp. 365-382
Open Access | Times Cited: 128
Epigenetic polypharmacology: A new frontier for epi‐drug discovery
Daniela Tomaselli, Alessia Lucidi, Dante Rotili, et al.
Medicinal Research Reviews (2019) Vol. 40, Iss. 1, pp. 190-244
Open Access | Times Cited: 96
Daniela Tomaselli, Alessia Lucidi, Dante Rotili, et al.
Medicinal Research Reviews (2019) Vol. 40, Iss. 1, pp. 190-244
Open Access | Times Cited: 96
Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells
Giovanni Nassa, Annamaria Salvati, Roberta Tarallo, et al.
Science Advances (2019) Vol. 5, Iss. 2
Open Access | Times Cited: 79
Giovanni Nassa, Annamaria Salvati, Roberta Tarallo, et al.
Science Advances (2019) Vol. 5, Iss. 2
Open Access | Times Cited: 79
MLL-Rearranged Acute Lymphoblastic Leukemia
Firas El Chaer, Michael Keng, Karen K. Ballen
Current Hematologic Malignancy Reports (2020) Vol. 15, Iss. 2, pp. 83-89
Closed Access | Times Cited: 71
Firas El Chaer, Michael Keng, Karen K. Ballen
Current Hematologic Malignancy Reports (2020) Vol. 15, Iss. 2, pp. 83-89
Closed Access | Times Cited: 71
Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias
Yan Yi, Shenglei Ge
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 40
Yan Yi, Shenglei Ge
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 40
Epigenetic Regulators as the Gatekeepers of Hematopoiesis
Cecília Pessoa Rodrigues, Maria Shvedunova, Asifa Akhtar
Trends in Genetics (2020) Vol. 37, Iss. 2, pp. 125-142
Open Access | Times Cited: 65
Cecília Pessoa Rodrigues, Maria Shvedunova, Asifa Akhtar
Trends in Genetics (2020) Vol. 37, Iss. 2, pp. 125-142
Open Access | Times Cited: 65
Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia
Zhiyu Zhang, Jiayi Huang, Zhibo Zhang, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 8
Zhiyu Zhang, Jiayi Huang, Zhibo Zhang, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 8
DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment
Federica Sarno, Angela Nebbioso, Lucia Altucci
Epigenetics (2019) Vol. 15, Iss. 5, pp. 439-453
Open Access | Times Cited: 53
Federica Sarno, Angela Nebbioso, Lucia Altucci
Epigenetics (2019) Vol. 15, Iss. 5, pp. 439-453
Open Access | Times Cited: 53
DOT1L O-GlcNAcylation promotes its protein stability and MLL-fusion leukemia cell proliferation
Tanjing Song, Qingli Zou, Yingying Yan, et al.
Cell Reports (2021) Vol. 36, Iss. 12, pp. 109739-109739
Open Access | Times Cited: 39
Tanjing Song, Qingli Zou, Yingying Yan, et al.
Cell Reports (2021) Vol. 36, Iss. 12, pp. 109739-109739
Open Access | Times Cited: 39
Targeting epigenetic regulation for cancer therapy using small molecule inhibitors
Amit Kumar, Luni Emdad, Paul B. Fisher, et al.
Advances in cancer research (2023), pp. 73-161
Closed Access | Times Cited: 15
Amit Kumar, Luni Emdad, Paul B. Fisher, et al.
Advances in cancer research (2023), pp. 73-161
Closed Access | Times Cited: 15
Conserved crosstalk between histone deacetylation and H3K79 methylation generates DOT1L‐dose dependency in HDAC1‐deficient thymic lymphoma
Hanneke Vlaming, Chelsea McLean, Tessy Korthout, et al.
The EMBO Journal (2019) Vol. 38, Iss. 14
Open Access | Times Cited: 40
Hanneke Vlaming, Chelsea McLean, Tessy Korthout, et al.
The EMBO Journal (2019) Vol. 38, Iss. 14
Open Access | Times Cited: 40
Mapping and targeting of the leukemic microenvironment
Matthew T. Witkowski, Stavroula Kousteni, Iannis Aifantis
The Journal of Experimental Medicine (2019) Vol. 217, Iss. 2
Open Access | Times Cited: 36
Matthew T. Witkowski, Stavroula Kousteni, Iannis Aifantis
The Journal of Experimental Medicine (2019) Vol. 217, Iss. 2
Open Access | Times Cited: 36
Advances in Epigenetic Cancer Therapeutics
Christopher Hillyar, Kathrine S Rallis, Jajini S. Varghese
Cureus (2020)
Open Access | Times Cited: 33
Christopher Hillyar, Kathrine S Rallis, Jajini S. Varghese
Cureus (2020)
Open Access | Times Cited: 33
TAZ/YAP fusion proteins: mechanistic insights and therapeutic opportunities
Keith Garcia, Anne‐Claude Gingras, Kieran F. Harvey, et al.
Trends in cancer (2022) Vol. 8, Iss. 12, pp. 1033-1045
Open Access | Times Cited: 22
Keith Garcia, Anne‐Claude Gingras, Kieran F. Harvey, et al.
Trends in cancer (2022) Vol. 8, Iss. 12, pp. 1033-1045
Open Access | Times Cited: 22
DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition
V.S.S. Abhinav Ayyadevara, Gerald Wertheim, Shikha Gaur, et al.
Leukemia (2025)
Open Access
V.S.S. Abhinav Ayyadevara, Gerald Wertheim, Shikha Gaur, et al.
Leukemia (2025)
Open Access
Fascinating Transformation of SAM-Competitive Protein Methyltransferase Inhibitors from Nucleoside Analogues to Non-Nucleoside Analogues
Arindam Talukdar, Ayan Mukherjee, Debomita Bhattacharya
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 3, pp. 1662-1684
Closed Access | Times Cited: 17
Arindam Talukdar, Ayan Mukherjee, Debomita Bhattacharya
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 3, pp. 1662-1684
Closed Access | Times Cited: 17
Tackling malignant melanoma epigenetically: histone lysine methylation
Elias Orouji, Jochen Utikal
Clinical Epigenetics (2018) Vol. 10, Iss. 1
Open Access | Times Cited: 29
Elias Orouji, Jochen Utikal
Clinical Epigenetics (2018) Vol. 10, Iss. 1
Open Access | Times Cited: 29
DOT1L activity in leukemia cells requires interaction with ubiquitylated H2B that promotes productive nucleosome binding
Cathy J. Spangler, Satya P. Yadav, Dongxu Li, et al.
Cell Reports (2022) Vol. 38, Iss. 7, pp. 110369-110369
Open Access | Times Cited: 15
Cathy J. Spangler, Satya P. Yadav, Dongxu Li, et al.
Cell Reports (2022) Vol. 38, Iss. 7, pp. 110369-110369
Open Access | Times Cited: 15
Advances in the Delivery and Development of Epigenetic Therapeutics for the Treatment of Cancer
Aparajita Ghosh, Ambati Himaja, Swati Biswas, et al.
Molecular Pharmaceutics (2023) Vol. 20, Iss. 12, pp. 5981-6009
Closed Access | Times Cited: 9
Aparajita Ghosh, Ambati Himaja, Swati Biswas, et al.
Molecular Pharmaceutics (2023) Vol. 20, Iss. 12, pp. 5981-6009
Closed Access | Times Cited: 9
Targeted therapy for fusion-driven high-risk acute leukemia
Yana Pikman, Kimberly Stegmaier
Blood (2018) Vol. 132, Iss. 12, pp. 1241-1247
Open Access | Times Cited: 27
Yana Pikman, Kimberly Stegmaier
Blood (2018) Vol. 132, Iss. 12, pp. 1241-1247
Open Access | Times Cited: 27
How to effectively treat acute leukemia patients bearing MLL-rearrangements ?
Dieter Steinhilber, Rolf Marschalek
Biochemical Pharmacology (2017) Vol. 147, pp. 183-190
Open Access | Times Cited: 26
Dieter Steinhilber, Rolf Marschalek
Biochemical Pharmacology (2017) Vol. 147, pp. 183-190
Open Access | Times Cited: 26
Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis
Xiong Zhang, Xingling Zheng, Hong Yang, et al.
Cancer Letters (2018) Vol. 431, pp. 150-160
Closed Access | Times Cited: 25
Xiong Zhang, Xingling Zheng, Hong Yang, et al.
Cancer Letters (2018) Vol. 431, pp. 150-160
Closed Access | Times Cited: 25
DOT1L inhibition enhances pluripotency beyond acquisition of epithelial identity and without immediate suppression of the somatic transcriptome
Coral K. Wille, Rupa Sridharan
Stem Cell Reports (2022) Vol. 17, Iss. 2, pp. 384-396
Open Access | Times Cited: 14
Coral K. Wille, Rupa Sridharan
Stem Cell Reports (2022) Vol. 17, Iss. 2, pp. 384-396
Open Access | Times Cited: 14
